LT3418300T - Neutralizuojantys antikūnai prieš gripo virusą a ir jų panaudojimas - Google Patents

Neutralizuojantys antikūnai prieš gripo virusą a ir jų panaudojimas

Info

Publication number
LT3418300T
LT3418300T LTEP18180926.0T LT18180926T LT3418300T LT 3418300 T LT3418300 T LT 3418300T LT 18180926 T LT18180926 T LT 18180926T LT 3418300 T LT3418300 T LT 3418300T
Authority
LT
Lithuania
Prior art keywords
influenza
neutralizing anti
virus antibodies
antibodies
virus
Prior art date
Application number
LTEP18180926.0T
Other languages
English (en)
Inventor
Antonio Lanzavecchia
Original Assignee
Institute For Research In Biomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute For Research In Biomedicine filed Critical Institute For Research In Biomedicine
Publication of LT3418300T publication Critical patent/LT3418300T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/11Orthomyxoviridae, e.g. influenza virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/10Detection of antigens from microorganism in sample from host
LTEP18180926.0T 2011-07-18 2011-07-18 Neutralizuojantys antikūnai prieš gripo virusą a ir jų panaudojimas LT3418300T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2011/002329 WO2013011347A1 (en) 2011-07-18 2011-07-18 Neutralizing anti-influenza a virus antibodies and uses thereof
EP18180926.0A EP3418300B1 (en) 2011-07-18 2011-07-18 Neutralizing anti-influenza a virus antibodies and uses thereof

Publications (1)

Publication Number Publication Date
LT3418300T true LT3418300T (lt) 2021-01-11

Family

ID=44993618

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP11784765.7T LT2734545T (lt) 2011-07-18 2011-07-18 Antikūnai, neutralizuojantys influenza a virusą, ir jų panaudojimo būdai
LTEP18180926.0T LT3418300T (lt) 2011-07-18 2011-07-18 Neutralizuojantys antikūnai prieš gripo virusą a ir jų panaudojimas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP11784765.7T LT2734545T (lt) 2011-07-18 2011-07-18 Antikūnai, neutralizuojantys influenza a virusą, ir jų panaudojimo būdai

Country Status (15)

Country Link
US (3) US9587010B2 (lt)
EP (3) EP3812397A1 (lt)
JP (1) JP6035332B2 (lt)
CN (1) CN103717617B (lt)
AU (1) AU2011373387B2 (lt)
CA (1) CA2841551C (lt)
DK (2) DK2734545T3 (lt)
ES (2) ES2841899T3 (lt)
HR (2) HRP20190714T1 (lt)
HU (2) HUE044089T2 (lt)
LT (2) LT2734545T (lt)
MX (1) MX352338B (lt)
PL (2) PL2734545T3 (lt)
SI (2) SI2734545T1 (lt)
WO (1) WO2013011347A1 (lt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2010009271A2 (en) 2008-07-15 2010-01-21 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
WO2011143262A2 (en) 2010-05-10 2011-11-17 Sinica, Academia Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
EP3812397A1 (en) 2011-07-18 2021-04-28 Institute for Research in Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
CN107417789A (zh) * 2011-07-18 2017-12-01 生物医学学会 中和抗甲型流感病毒抗体及其用途
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
EP2885311B1 (en) 2012-08-18 2020-01-01 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
WO2014031762A1 (en) 2012-08-21 2014-02-27 Academia Sinica Benzocyclooctyne compounds and uses thereof
EA201590731A1 (ru) 2012-11-13 2015-11-30 Дженентек, Инк. Антитела к гемагглютинину и способы применения
KR20140118682A (ko) * 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 a 바이러스 중화 결합 분자를 포함하는 조성물
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
EP3041484B1 (en) 2013-09-06 2021-03-03 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
CN113667013B (zh) * 2013-10-02 2024-04-09 免疫医疗有限责任公司 中和抗甲型流感抗体及其用途
KR20160104727A (ko) 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
AU2015231164B2 (en) * 2014-03-19 2020-04-09 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
WO2015166329A1 (en) 2014-05-01 2015-11-05 Indian Institute Of Science Polypeptides for generating anti-influenza antibodies and uses thereof
JP7093612B2 (ja) 2014-05-27 2022-06-30 アカデミア シニカ Bacteroides由来のフコシダーゼおよびそれを使用する方法
TWI670078B (zh) 2014-05-27 2019-09-01 中央研究院 抗cd20醣抗體及其用途
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7062361B2 (ja) 2014-05-27 2022-05-06 アカデミア シニカ 抗her2糖操作抗体群およびその使用
US11332523B2 (en) 2014-05-28 2022-05-17 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
CN113173990A (zh) 2014-07-15 2021-07-27 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
JP6899321B2 (ja) 2014-09-08 2021-07-07 アカデミア シニカAcademia Sinica 糖脂質を使用するヒトiNKT細胞活性化
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2972072A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
KR20170107562A (ko) 2015-02-05 2017-09-25 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 적혈구응집소에 대한 결합 분자 및 이의 용도
GB201502137D0 (en) * 2015-02-09 2015-03-25 Ucl Business Plc Treatment
KR20170133507A (ko) * 2015-04-08 2017-12-05 다나-파버 캔서 인스티튜트 인크. 인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법
SI3303384T1 (sl) 2015-06-01 2021-11-30 Medimmune Llc Nevtralizirajoče vezavne molekule proti-influenci in njihova uporaba
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
EP3402513A4 (en) * 2016-01-13 2019-10-23 Medlmmune, LLC METHOD OF TREATING A FLU
US20170240617A1 (en) 2016-02-24 2017-08-24 Visterra, Inc. Formulations of antibody molecules to influenza virus
TW201808978A (zh) 2016-03-08 2018-03-16 中央研究院 N-聚醣及其陣列之模組化合成方法
WO2017192589A1 (en) * 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
KR20220035288A (ko) * 2016-05-05 2022-03-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 인플루엔자 바이러스를 표적으로 하는 dna 단일 클론 항체
CN109963868B (zh) 2016-08-22 2023-11-14 醣基生医股份有限公司 抗体、结合片段及使用方法
WO2018038096A1 (ja) * 2016-08-23 2018-03-01 国立大学法人東京大学 モノクローナル抗体又はその抗原結合フラグメント及びその使用
CN107868121B (zh) * 2016-09-28 2021-03-16 中国医学科学院病原生物学研究所 H3亚型流感病毒血凝素特异性保守表位、其抗体及其应用
CA3051377A1 (en) 2017-01-27 2018-08-02 National Research Council Of Canada Hemagglutinin-specific antibodies and uses thereof
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2021055798A1 (en) * 2019-09-19 2021-03-25 Duke University Influenza neutralizing antibodies and their uses
US20220267382A1 (en) * 2019-09-20 2022-08-25 Academia Sinica Chimeric hemagglutinin protein and a vaccine composition comprising the same
IL293804A (en) 2019-12-11 2022-08-01 Visterra Inc Anti-hemagglutinin (ha) antibody molecules, preparations containing them and their uses
CA3237090A1 (en) * 2021-11-05 2023-05-11 Dana-Farber Cancer Institute, Inc. Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
CN117430664B (zh) * 2023-10-24 2024-04-09 暨南大学附属第六医院(东莞市东部中心医院) 一种甲型流感病毒t细胞抗原表位肽及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB819376A (en) 1956-10-20 1959-09-02 Colne Switchgear K & W Ltd Improvements in electro-magnetic overload units for electrical apparatus
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
AU8063798A (en) 1997-06-19 1999-01-04 Regents Of The University Of California, The Secretory immunoglobulin produced by single cells and methods for making and using same
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
EP1264885A4 (en) 2000-02-22 2007-02-21 Med & Biological Lab Co Ltd ANTIBODY LIBRARY
WO2004007667A2 (en) 2002-07-11 2004-01-22 The General Hospital Corporation Polynucleotide and polypeptide fat metabolism regulators and uses thereof
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
CN1756562A (zh) * 2003-03-07 2006-04-05 麦克公司 流感病毒疫苗
CN103446582A (zh) 2003-08-11 2013-12-18 财团法人阪大微生物病研究会 包含诱导粘膜免疫的佐剂的新型疫苗
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
EP2522678A1 (en) 2006-05-15 2012-11-14 Sea Lane Biotechnologies, LLC Neutralizing antibodies to influenza viruses
US8192927B2 (en) 2006-09-07 2012-06-05 Crucell Holland B.V. Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof
CN101541832B (zh) * 2006-09-07 2014-11-12 克鲁塞尔荷兰公司 能中和流感病毒h5n1的人结合分子及其应用
HUE054090T2 (hu) 2006-10-02 2021-08-30 Regeneron Pharma A humán IL-4 receptorral szemben nagy affinitást mutató humán antitestek
EP2094307A4 (en) 2006-11-08 2015-08-26 Macrogenics West Inc TES7 AND THEREO BINDING ANTIBODIES
EP1925318A1 (en) 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
CN102046654A (zh) 2007-03-13 2011-05-04 胡马斯有限公司 针对甲型流感病毒h5n1株系的抗体
SG187500A1 (en) 2008-01-21 2013-02-28 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
RU2553325C2 (ru) 2008-07-25 2015-06-10 Институт Фо Ресёч Ин Биомедицин Нейтрализующие антитела против вируса гриппа а и их использование
ES2525346T3 (es) 2008-10-22 2014-12-22 Institute For Research In Biomedicine Métodos para producir anticuerpos a partir de células plasmáticas
US9051359B2 (en) 2009-03-30 2015-06-09 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
MX349924B (es) 2009-06-24 2017-08-21 Medicago Inc * Partículas similares al virus de la influenza quiméricas que comprenden hemaglutinina.
EP3812397A1 (en) 2011-07-18 2021-04-28 Institute for Research in Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof

Also Published As

Publication number Publication date
DK2734545T3 (en) 2019-04-15
MX352338B (es) 2017-11-17
MX2014000749A (es) 2014-05-07
DK3418300T3 (da) 2020-12-07
HUE051756T2 (hu) 2021-03-29
HRP20201975T1 (hr) 2021-02-05
SI2734545T1 (sl) 2019-06-28
EP2734545A1 (en) 2014-05-28
PL3418300T3 (pl) 2021-05-04
EP2734545B1 (en) 2019-03-27
US20140271655A1 (en) 2014-09-18
CA2841551C (en) 2020-07-28
CN103717617A (zh) 2014-04-09
JP2014523254A (ja) 2014-09-11
US9587010B2 (en) 2017-03-07
EP3812397A1 (en) 2021-04-28
CN103717617B (zh) 2017-06-20
CA2841551A1 (en) 2013-01-24
US20190248874A1 (en) 2019-08-15
SI3418300T1 (sl) 2021-03-31
EP3418300B1 (en) 2020-10-28
ES2732552T3 (es) 2019-11-25
EP3418300A1 (en) 2018-12-26
AU2011373387A1 (en) 2014-01-23
US10815294B2 (en) 2020-10-27
AU2011373387B2 (en) 2017-06-29
HUE044089T2 (hu) 2019-09-30
HRP20190714T1 (hr) 2019-06-14
LT2734545T (lt) 2019-05-10
WO2013011347A1 (en) 2013-01-24
JP6035332B2 (ja) 2016-11-30
US20170204167A1 (en) 2017-07-20
PL2734545T3 (pl) 2019-09-30
ES2841899T3 (es) 2021-07-12

Similar Documents

Publication Publication Date Title
LT2734545T (lt) Antikūnai, neutralizuojantys influenza a virusą, ir jų panaudojimo būdai
HUS2100034I1 (hu) ANGPTL3-ellenes antitestek és alkalmazásaik
IL288203B (en) Meditops and Meditop binding antibodies and their use
ZA201403264B (en) Neutralizing gp41 antibodies and their use
IL232399A0 (en) Anti-2fgfr antibodies and their use
DK2729170T3 (en) Antibody variants and uses thereof
EP2663334A4 (en) ANTIBODIES AGAINST INFLUENZA
SG11201402780UA (en) Influenza a virus specific antibodies
EP2768858A4 (en) ANTI-INFLUENZA ANTIBODIES
SG10202103140XA (en) Neutralizing anti-influenza a antibodies and uses thereof
HK1199842A1 (en) Anti-siglec-15 antibodies and uses thereof -15